Kenneth Bate has demonstrated a clear selling bias in his recent insider transactions, primarily involving shares of Madrigal Pharmaceuticals (MDGL). Between August and November 2025, Bate executed 17 sales totaling approximately $11.68 million, with no offsetting purchases during that period. The most concentrated selling occurred on November 5, 2025, when he disposed of MDGL shares across 13 separate transactions ranging from $14,729 to $1.57 million, including a single $3.04 million transaction coded as a derivative disposition. Earlier, on August 15, 2025, he sold another $3.66 million worth of MDGL stock in six transactions, supplemented by a $164,600 derivative transaction. While Bate also holds shares in Astria Therapeutics (ATXS), his January 2026 filings for that position show no monetary value changes, indicating either non-monetary adjustments or minimal economic impact. His overall trading history shows $3.56 million in lifetime buys against $11.68 million in sales, with all recent activity skewed toward divestment. The transactions suggest an ongoing reduction in Bate's MDGL position, though the consistent multi-year involvement with the company indicates retained exposure despite the selling pattern.
AI-assisted summary